Viewing Study NCT00002527



Ignite Creation Date: 2024-05-05 @ 11:21 AM
Last Modification Date: 2024-10-26 @ 9:03 AM
Study NCT ID: NCT00002527
Status: COMPLETED
Last Update Posted: 2016-07-04
First Post: 1999-11-01

Brief Title: Aspirin in Treating Patients With Colorectal Cancer That Has Been Surgically Removed
Sponsor: Alliance for Clinical Trials in Oncology
Organization: Alliance for Clinical Trials in Oncology

Study Overview

Official Title: Colorectal Adenoma Chemoprevention Trial Using Aspirin A Phase III Study
Status: COMPLETED
Status Verified Date: 2016-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: RATIONALE Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer The use of aspirin may be an effective way to prevent the recurrence of polyps in colorectal cancer

PURPOSE Randomized phase III trial to study the effectiveness of aspirin in treating patients who have stage I stage II or stage III colorectal cancer that has been surgically removed
Detailed Description: OBJECTIVES I Determine whether aspirin administered at a dose of 325 mgday will decrease the number and size of new adenomas in patients with Dukes AB1B2C colorectal cancer who have undergone curative surgical resection II Assess whether this dose of aspirin will increase disease-free survival in these patients

OUTLINE Randomized double-blind study Arm I Chemoprevention Enteric-coated Aspirin ASA NSC-27223 Arm II Control Placebo PLCB

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
CDR0000078380 REGISTRY NCI Physician Data Query None
CLB-9270 None None None
E-C9270 None None None
NCCTG-949251 None None None
NCI-P93-0048 None None None